MimiVax and Roswell Park Comprehensive Cancer Center have announced results from the SURVIVE Phase IIb clinical trial evaluating novel cancer vaccine, SurVaxM, in patients with newly diagnosed glioblastoma. The data reflect the first reportable results from the fully enrolled clinical trial, which has been underway since 2022… Read More
Scientists have identified a brief window after brain tumour surgery during which a treatment for glioblastoma can cross the brain’s protective barrier and reach the cancer cells most likely to trigger tumour regrowth. The discovery could pave the way for more effective treatments for glioblastoma, the most… Read More
PhoreMost has announced a treatment for brain cancers as its lead programme, also appointing Dr Gabriel Fox as Chief Medical Officer. The biotechnology company will progress PMC-001, a next-generation, small molecule microtubule targeting agent (MTA) for primary and secondary brain cancers, towards Phase I clinical trial. PMC-001 is… Read More
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a UK group accelerated efforts to develop a vaccine for Ebolavirus. Elsewhere,… Read More
News round-up for 25–29 May by Bruno Quinney, Content Team at DDW. This week, a UK group has accelerated efforts to develop a vaccine for Ebolavirus. Elsewhere, significant findings in colorectal and brain cancer could shape future cancer treatments. The top stories: UK group steps… Read More
Brain cancer could be treated more easily using stem cells from the lining of the mouth, new research suggests. Scientists at the University of Reading found that when stem cells from the mouth were transplanted into mouse brain tissue, they slowed cancer growth and reduced the size… Read More
A new study into brain metastasis has identified an immune target with translational potential. The study, conducted by researchers at the Spanish National Cancer Research Centre (CNIO), has identified macrophage migration inhibitory factor (MIF)–mediated reprogramming of CD74‑positive microglia and macrophages as a central vulnerability in brain metastasis. Read More
An innovative gene therapy could achieve complete tumour elimination in brain cancer, data shows. Biotechnology company Trogenix has announced the publication of breakthrough preclinical data, reporting complete tumour eradication and durable protection in a state-of-the-art aggressive brain cancer model that closely mimics human glioblastoma (GBM). The results, published in … Read More
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, innovative therapies showed the way to more effective cancer treatments. Elsewhere, how can… Read More
News round-up for 2 – 6 February by Bruno Quinney, Content Team at DDW. This week in DDW, innovative therapies could pave the way to more effective cancer treatments. Elsewhere, how can brain function be improved in Alzheimer’s patients? The top stories: Immunotherapy before surgery… Read More
The US Food and Drug Administration (FDA) has cleared Siren Biotechnology’s first Investigational New Drug (IND) application for its AAV immuno-gene therapy for cancer, enabling the initiation of its first-in-human clinical trial. The IND clearance supports the evaluation of Siren’s lead investigational programme in adult patients with… Read More
The European Commission has approved pharmaceutical company Servier’s Voranigo therapy for patients with a specific type of brain tumour. Voranigo has now been approved for the treatment of predominantly non-enhancing Grade 2 astrocytoma or oligodendroglioma with an isocitrate dehydrogenase-1 (IDH1) R132 or isocitrate dehydrogenase-2 (IDH2) R172 mutation… Read More
DDW Editor Reece Armstrong speaks to Dr Laura Aguilar, CMO of Diakonos Oncology, about the challenges of treating glioblastoma (GBM) and the approaches the company is taking to help tackle this devastating disease. RA: Why has GBM remained such a hard cancer to treat? LA: First, GBM, also known… Read More
The US Food and Drug Administration (FDA) has granted accelerated approval for Modeyso (dordaviprone) for the treatment of patients one year of age and older with diffuse midline glioma harbouring an H3 K27M mutation with progressive disease following prior therapy. The FDA has stated that continued approval… Read More
Scientists have demonstrated that glioblastoma (GBM) tumour stem cells became less able to proliferate and invade tissues when the production of the prion protein was blocked, highlighting a potential new therapeutic target. GBM, which accounts for nearly half (49%) of all brain tumours, has an extremely low… Read More
An experimental cancer treatment developed by researchers at the Melanoma Institute Australia paves the way for a clinical trial to be conducted by researchers at the Brain Cancer Centre in Melbourne. It is the first documented use of neoadjuvant triple immunotherapy in glioblastoma, involving a combination of… Read More
